Welcome to our dedicated page for Precipio SEC filings (Ticker: PRPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precipio, Inc. filings document the public-company disclosures of a specialty cancer diagnostics issuer with Pathology Services and Products operations. Its Form 8-K reports include Regulation FD updates for shareholder calls and investor presentations, furnished financial results, and material-event disclosures related to corporate communications and operating performance.
The company’s proxy materials describe annual meeting procedures, stockholder voting matters, governance, and access to annual reporting materials. Other filings document capital-structure matters, including common stock activity and the termination of an at-the-market sales agreement, alongside formal exhibits and disclosures tied to Precipio’s diagnostics business and shareholder communications.
Precipio, Inc. reported sharply higher activity but continued losses for the three months ended March 31, 2026. Net sales rose to $6.7M from $4.9M, driven by service revenue, as cases processed increased to 4,912 from 3,021. Gross profit improved to $2.7M, though gross margin dipped to 41% from 43% due to lower average price per case.
The company recorded a net loss of $1.4M versus $0.9M a year earlier, with higher operating expenses including $1.0M of stock-based compensation. Cash was $2.6M and working capital $2.1M, with slightly positive operating cash flow of $0.1M. Management states there is substantial doubt about Precipio’s ability to continue as a going concern without additional revenue growth or financing.
Precipio, Inc. is organizing a Q1-2026 shareholder update call on May 18, 2026 at 5:00 PM ET. Management plans to discuss the company’s current core businesses and overall performance, strategy, and growth initiatives.
For the first time, the quarterly update will feature a dedicated, moderated live Q&A session, allowing investors and other listeners to submit questions during the call or in advance by email. Participants can join by calling 646.307.1865, and a replay will be available on the Investors section of Precipio’s website.
Precipio, Inc. has called its 2026 virtual Annual Meeting of Stockholders for June 15, 2026, at 10 a.m. Eastern Time. Stockholders of record as of April 21, 2026, holding 1,784,830 shares of common stock in total, may attend online, ask questions, and vote using a 16-digit control number.
The agenda includes electing three Class II directors—Richard Sandberg, Christina Valauri, and Jeffrey Cossman, M.D.—to terms expiring in 2029 and ratifying CBIZ CPAs, P.C. as independent auditor for the year ending December 31, 2026. The board and all key committees are majority independent, with separate chair and CEO roles, and have adopted policies on board diversity, ESG oversight, insider trading, and compensation clawbacks.
The filing details beneficial ownership, with directors and executive officers as a group holding 324,799 shares, or 16.6% of common stock as of the record date. It also outlines director cash retainers and stock option grants, and executive pay that combines salaries, deferred bonus opportunities, and equity awards designed to align leadership incentives with long-term stockholder value.
Valauri Christina Rizopoulos reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director Christina Rizopoulos Valauri received a grant of 93 shares of Common Stock on April 15, 2026. According to the footnote, this stock grant was provided as consideration in lieu of cash for her compensation for service on the Board of Directors for Q1-25. Following this equity award, she directly owns 5,520 shares of Precipio common stock.
Cossman Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director Jeffrey Cossman received a grant of 365 shares of common stock on April 15, 2026. The shares were issued at $29.49 per share as compensation in lieu of cash for his Board of Directors service for Q1-26, bringing his direct holdings to 16,133 shares.
Cohen David Seth reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director David Seth Cohen received a grant of 445 shares of common stock on April 15, 2026. The shares were issued at $29.49 per share as compensation in lieu of a cash payment for his Board of Directors service for Q1-26. Following this grant, his direct holdings increased to 54,679 common shares.
Precipio, Inc. Chief Operating Officer Ahmed Zaki reported an open-market purchase of common stock. On April 1, 2026, he bought 19 shares at $27.93 per share, increasing his direct holdings to 1,034 shares. The purchase was made under a pre-arranged Rule 10b5-1 trading plan.
Precipio, Inc. files its annual report describing an integrated cancer diagnostics business built around pathology services and proprietary products such as HemeScreen and IV-Cell. The company targets U.S. oncology labs and cites large addressable markets in oncology testing and diagnostic products.
For the year ended December 31, 2025, Precipio recorded an operating loss of $1.2 million, an accumulated deficit of $102.8 million, cash of $2.6 million and working capital of $2.3 million, leading auditors to express substantial doubt about its ability to continue as a going concern. One customer represented 26% of 2025 revenue, and government programs accounted for about 40% of revenue.
The company spent $1.6 million on research and development in 2025, continues to pursue patent protection for its technologies, and operates under complex U.S. and international regulatory regimes, including FDA, CLIA, EU IVDR, UKCA, HIPAA, GDPR and emerging state privacy laws. Management highlights liquidity needs, reimbursement risk, regulatory change, climate-related and macroeconomic pressures as key risk factors.
Precipio, Inc. reported preliminary, unaudited results showing a strong finish to 2025. Full-year 2025 revenues grew about 30% year-over-year. In Q4-2025, the company generated approximately $0.4 million in operating cash flow, reflecting a shift to cash-flow positivity.
Q4-2025 net income was about $0.5 million under GAAP, compared with a net loss of roughly $0.4 million in Q4-2024. Q4-2025 EBITDA was about $0.9 million, and Adjusted EBITDA was about $1.0 million, up from approximately $0.0 million and $0.4 million respectively in Q4-2024.
Management highlights becoming EBITDA- and cash-flow-positive as a key milestone that may allow greater focus on longer-term growth projects. More detailed discussion is expected on a shareholder call in early April, following the planned Form 10-K filing.